Table 2

Comparison of frequency of SAEs according to SARS-CoV-2 test results between treatment received

CT
n=50
TT
n=84
ICI
n=159
Overall
n=293
SARS-CoV-2-positive patients 13 (26.0) 24 (28.6) 52 (32.7) 89 (30.4)
No occurrence of SAE11 (84.6)24 (100.0)43 (82.7)
Occurrence of SAE2 (15.4)9 (17.3)
SARS-CoV-2-negative patients 37 (74.0) 60 (71.4) 107 (67.3) 204 (69.6)
No occurrence of SAE36 (97.3)60 (100.0)103 (96.3)
Occurrence of SAE1 (2.7)4 (3.7)
CMH test* 0.0008*
Breslow-Day test* 0.8909
  • *Breslow-Day test: tests the homogeneity of the OR between the two groups.

  • †CMH: Cochran-Mantel-Haenszel test: tests the conditional independence between SAE and SARS-CoV-2 test result controlling for the type of therapy.

  • .CT, chemotherapy; ICI, immune checkpoint inhibitors; SAE, serious adverse event; TT, targeted therapy.